Compare SVC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVC | MNKD |
|---|---|---|
| Founded | 1995 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1995 | 2004 |
| Metric | SVC | MNKD |
|---|---|---|
| Price | $8.07 | $4.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $2.50 | ★ $8.69 |
| AVG Volume (30 Days) | 3.1M | ★ 4.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | ★ 26.95 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,814,838,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | $1.39 | $11.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $1.13 | $2.23 |
| 52 Week High | $9.02 | $6.51 |
| Indicator | SVC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 73.14 | 46.44 |
| Support Level | $1.55 | $3.81 |
| Resistance Level | $9.02 | $3.94 |
| Average True Range (ATR) | 0.32 | 0.21 |
| MACD | -0.20 | -0.04 |
| Stochastic Oscillator | 3.74 | 26.65 |
Service Properties Trust is a real estate investment trust that owns hotel properties. These properties are located in the United States, along with Canada and Puerto Rico. The company operates through its segments hotel investment unit, and net lease investments. The firm derives the majority of its revenue from the hotel real estate investments unit. The hotels are distinguished between their service levels, which include full service, select service, and extended stay; and chain scale, which includes luxury, upper upscale, upscale, upper midscale, and midscale. The hotels are extended stay or upscale. Some of the hotel brands include Courtyard by Marriott, Royal Sonesta, Crowne Plaza, Hyatt Place, and others.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.